Increasing Collaboration to Lower System Cost and Deliver Value: Insights From ASH 2016

Posted by Christina Corridon on Dec 22, 2016 11:13:31 AM

Meadow Green co-wrote this post with Christina Corridon.

In addition to its coverage on value in cancer treatments, the 2016 American Society of Hematology (ASH) Annual Meeting also featured sessions that highlighted how players in a rapidly evolving healthcare delivery ecosystem can collaborate to deliver value and lower system costs.


>
Read More

Driving Treatment Value: Insights From ASH 2016

Posted by Christina Corridon on Dec 21, 2016 9:22:36 AM

Meadow Green co-wrote this post with Christina Corridon.

The 2016 American Society of Hematology (ASH) Annual Meeting was rich with clinical updates and innovations to advance care and improve life for patients with hematologic cancers. However, as life is prolonged among chronic and acute diseases, payers, providers and patients are wrestling with the cost of therapy over months and even years—a topic that came up many times during various sessions at ASH.


>
Read More

Keeping Up With CAR-T: The Most Crowded Room at ASH

Posted by Maria Whitman on Dec 9, 2016 11:29:40 AM


Bernadette Bourjolly and Pranav Srivastava contributed to this blog post.

As I rounded the corner in the north tower of the Marriott hotel next to the San Diego Convention Center while attending the American Society of Hematology (ASH) Annual Meeting this past weekend, I was suddenly met by a sea of bodies straining to see ahead. Many were trying to push through, anxious to be on time for a main session on advances in immunotherapy for acute lymphoblastic leukemia. The ballroom was already full, and the ground staff was working feverishly to acquire an overflow room. One frustrated doctor next to me let out a sigh and said: “You think they would have learned from prior years. The CAR-T sessions need a main hall.” An overflow room opened next to where I was standing and I slipped inside, feeling lucky to grab a seat before the room filled and the process began again, causing many to miss some of the opening abstract presentation.


>
Read More

Is the CAR-T Upset?

Posted by Pranav Srivastava on Dec 1, 2016 12:38:37 PM

Recently, Juno Therapeutics announced that it’s putting a clinical trial for one of its CAR (chimeric antigen receptor) T-cell therapy candidates (JCAR015) on hold, even though it remains unclear whether the patient deaths in one of its trials were drug related. Following the news, the company’s stock took a beating before Thanksgiving, dropping nearly a quarter of its value. Prior to the two patient deaths—both suffered from swelling of the brain—the broad range of neurotoxicity had been a known challenge with CAR-Ts. With the latest news, we once again are faced with questions: Is this when the shine starts to come off? Are we seeing the reality beyond the hype? 


>
Read More

ASH 2016: Have Combination Regimens Arrived Yet?

Posted by Pranav Srivastava on Nov 23, 2016 9:20:07 AM


In a few short years, the treatment landscape for patients with hematologic malignancies has been transformed into a world of choices. The upcoming American Society of Hematology (ASH) Annual Meeting, which will be held Dec. 3-6 in San Diego, will bring more data to the forefront—with much more to come in the next five years—that builds on the recent trend of attacking cancer via multiple pathways through combination therapy regimens.

So far, the event abstracts already show a wide array of combination therapies in most tumor types: acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia, among many others. As the data for combination regimens continues to build, we expect many more approvals in the next few years, and with this ever-lengthening list of combination therapies comes greater hope for patients.


>
Read More